Objective: The patients after myocardial infarction could hope for a significant improvement in their life expectancy when complying with the principles of the secondary prevention. Today there is no doubt that the administration of ACE-inhibitors, beta-blockers, aspirin and statins decrease mortality in these patients. Although the clinicians are aware of the guidelines of Evidence Based Medicine, international and Hungarian surveys show that in their everyday application there is still much to improve.
INTRODUCTION
The mortality related to coronary heart disease is the leading cause of death in the industrialised countries, like Hungary and Czech Republic as well (1, 2) . In patients having survived an acute myocardial infarction (AMI) the incidence of cardiovascular risk factors is higher than in normal population (3) , and the probability of a new cardiovascular event is very high. 25% of the postMI men and 38% of women die in the first year (4). The life expectancy of these patients could be improved by their adherence to principles of prevention. Life-style change, risk factor interventions, together with appropriate drug therapy can reduce significantly the cardiovascular morbidity and mortality (5) . There are a lot of large, prospective, randomized studies proving the very favourable effect of antiplatelet, beta-blocker, ACE-inhibitor and statin therapy. The administration of aspirin is the most cost-effective in the improvement of life expectancy in postAMI patients (6, 7) , and betablockers could reduce the incidence of sudden cardiac death and reinfarction by 25% (8, 9, 0) . The use of ACE-inhibitors reduces the mortality by the regulation of neuroendocrine activation and remodeling inhibition (11, 12, 13) . The favourable effect of the lipid lowering therapy is at least as great as the use of other secondary prevention's drugs (14) . The 4S, CARE, LIPID and GREACE studies have shown a significant total and cardiovascular mortality reducing effect of statins in postAMI patients with high risk and considerably or slightly elevated serum cholesterol level (15, 16, 17, 18) . The administration of this group of drugs is recommended after the initiation of standard acute therapy in every patient with AMI having no contraindication.
Although the clinicians are aware of the guidelines of Evidence Based Medicine, international and Hungarian surveys show that in their everyday application there is much to improve. The Cardiovascular Hospitalization Atherosclerosis Management Program in Los Angeles proved that the beginning of application of secondary treatment options before discharge, during the hospital stay, determines positively the number of appropriately treated patients and the patients' compliance for a long time. Due to the education of nurses and physicians the use of lipid lowering drugs at the time of discharge increased from 6% to 86%, and that of aspirin, beta-blockers and ACE-inhibitors changed favourable as well (19) .
The EUROASPIRE I study was conducted between 1991 and 1995 in patients after AMI, acute coronary syndrome or percutaneous coronary intervention. 6 months after the event ¼ of patients were smokers, the cholesterol level was higher than 5.2 mmol/l at ¾ of them, and only 30% were taking beta-blocker and 75% aspirin (20) . According to the results of EUROASPIRE II, 4-5 years later, the administration of beta-blockers increased to 63%, that of aspirin to 86% (2) . In the Hungarian centers of this study, the proportion of patients taking aspirin and lipid lowering drugs was lower; the use of ACE-inhibitors and beta-blockers was higher (22) .
In the present study the frequency of administration of these drugs was investigated in patients treated because of AMI in the Coronary Care Unit of our internal medicine department with cardiological profile at the time of discharge and at the 6th months control examination. The accuracy of our recommendations with the former results in mind was evaluated.
pATIENTS AND METHODS
Beginning from 1 January 1999 the data of 200 consecutive patients, discharged from our department with AMI were analyzed retrospectively. The diagnosis of AMI (either ST segment elevation or non ST segment elevation) was established (based) on the clinical features, ECG and enzyme analysis. Based on the final reports' data the risk factors, lipid results and the medicines prescribed for the patients at the discharge time were analyzed, focusing on platelet inhibitors, ACE-inhibitors, beta-blockers and lipid lowering drugs.
90 patients had returned half year later for a control examination at our outpatient department and the administration of medicines suggested at the time of their hospital discharge was checked.
With the full knowledge of the previous results we looked over the medication of patients (with the same diagnosis) who were treated at our ward between 1 January-31 December 2002. We examined how the results of study between 1999-2000 influenced the subsequent drug recommendations. Our final results about the application of guidelines were compared with data of similar Hungarian and international studies.
RESULTS
After 1 January 1999 there were among 200 consecutive patients having survived acute myocardial infarction 115 (57.5%) men (mean age 64.7±10.6 years), and 85 (42.5%) women (mean age 68.9±10.9 years). 170 (85%, 100 men and 70 women) were admitted with ST segment elevation AMI (67 of them, 39.4% received thrombolytic therapy), 30 (15%, 15 men and 15 women) with non ST segment elevation AMI. 16% of the examined patients had AMI previously, 59% had hypertension, 25% suffered from diabetes, 12% had stroke and 15% had peripheral vascular disease in their history. 77% were overweight (BMI>25 kg/m 2 ), 62.4% were smoker. Although the analysis of lipid parameters was performed in the acute phase of AMI, when secondary to the acute phase reaction the results are inaccurate, in 75% of the patients the cholesterol level was higher than 5.2 mmol/l. The average cholesterol level proved to be 5.59±0.97 mmol/l, the LDL-cholesterol 3.62±0.89, the triacylglycerols 1.76±0.73, and the HDL-cholesterol 1.13±0.23 mmol/l.
At the time of hospital discharge 90% of patients were taking aspirin, 61% beta-blockers, 88% ACE-inhibitors and 51% lipid lowering drugs. Comparing our results with data of the Euro Heart Survey 2002 (23) it is apparent that treatment suggestions for antiplatelet drugs and ACE inhibitors occurred more frequently (90% vs. 86% and 88% vs. 57%) than that for β-receptor blockers (61% vs. 75%). The frequency of lipid lowering treatment was similar (51% vs. 53%).
Comparing our results with the data of Szeged Medical Center (24) we could establish, that the rate of aspirin and β-receptor-blockers use was lower (90% vs. 95% and 61% vs. 79%), the administration of ACE-inhibitors and mainly that of lipid lowering drugs occurred more often. (88% vs. 82% and 51% vs. 39%) (Fig. 1) . 90 of the 200 examined patients appeared for the half year cardiological control. This time 77% of the patients were recommended to take aspirin, 88% beta-blockers, 86% ACEinhibitors, and 48% lipid lowering drugs. Comparing our data with that EUROASPIRE II we gave ACE-inhibitors (86% vs. 57%), aspirin (77% vs. 75%), beta-receptor-blockers (88% vs. 84%) more frequently while the administration of lipid lowering drugs was similar (48% vs. 51%). (Fig. 2) . Concerning the achievement of target lipid levels, in this high risk population the LDL-cholesterol of 2.5 mmol/l was reached only in 7% of the patients at the 6 th months control. The target 4.5 mmol/l total cholesterol level was attained in 21%.
Being aware of the results of the study from 1999 and 2000 we examined the medication of the 165 patients having survived AMI, treated in 2002, at hospital discharge. We found that the previous, extremely low administration rate of beta-blockers increased significantly (61% vs. 89%). The same held true for aspirin and lipid lowering drugs, which increased only slightly from 90% vs. 96% and 51% vs. 57%, respectively. There was no change in the usage of the ACE-inhibitors (88% vs. 88%) (Fig. 3) .
DISCUSSION
Patients having survived AMI have a 5-7 times higher risk of the subsequent cardiovascular events than the population without known coronary disease. A large amount of great, prospective studies proved that in these high risk groups the proper treatment, the lifestyle change, the risk factor control could reduce the cardiovascular morbidity and mortality rate. Nowadays in Hungary about 25,000 AMI/year occur making thus in this group of patients the application of principles of secondary prevention the most cost-effective measure. However, in spite of the continually increasing strictness of the guidelines and decreasing target levels international and Hungarian experiences show that abundant unexploited reserves are available in the treatment of AMI. Doctors and special trained staff should collaborate closely with the patients, providing them information about keeping diet, physical exercises and healthy way of life and changing smoking habits. Vale et al. in their randomised controlled trial in patients with coronary heart disease in Australia found that the by 11% and 33%, respectively. Unfortunately, the administration of statins is lower in Hungarian surveys than in international ones. Nowadays, in the time of quality assurance we believe that it is not enough to know the latest principles of the Evidence Based Medicine, but we should apply them in the every day clinical practice as well. Pearson et al. found a significant difference between the knowledge of the principles of lipid lowering treatment and the target levels achieved (27) . That's why we have set ourselves an aim to review our clinical practice and check whether it corresponds with other published results. 90% of our patients having survived AMI in 1999 and 2000 were given antiplatelet therapy, 88% got ACE-inhibitor, 61% β-receptor-blocker and 51% of them took part in lipid lowering treatment at their hospital discharge. Comparing these results with international experiences we found that the application of ACE-inhibitors was higher, while that of β-receptor-blockers was lower than the international average. Studying our practice two years later the results showed that significant improvement occurred in administration of beta-blockers, slight increase in the antiplatelet and in lipid lowering treatment, with no change in the use of ACE-inhibitors. Considering the published international and Hungarian data, in our practice the application of aspirin was very high, above 90%. The administration of ACE-inhibitors in our department, in accordance with other Hungarian studies, is higher, than the international average. However there's a lag in using lipid lowering drugs but according to our data, improvement in this regard is expected, as well. Probably in a few years this kind of lipid lowering treatment, i.e. the application rate of statins, will increase due to the ever growing evidences on event reduction and the more advantageous financial conditions. In addition, more importance will be set on achieving the target lipid levels (5, 28), which, in accordance with results of the newest studies, will be, probably, even lower (29) .
In our study half year after AMI the drug review showed that administration of aspirin decreased (because of side effects, this is why new antiplatelet drugs should be used) no change occurred in the rate of ACE-inhibitor use and it was favourable, that more patients received beta-blocker treatment than at their hospital discharge.
Our data are comparable with international ones, in some cases our results are more favourable (ACE-inhibitors), but still significant reserves are available in the treatment of patients after AMI. Beside strict control and continuous education of patients the periodical review and check of the quality of our work are also necessary. According to our data the application rate of β-blockers increased by 48% between the 1999-2000 and the 2002 survey. The practical application of the ever growing principles of the evidence based medicine means a hard task for the physicians, which on a proper level -we believe -only with continuous self-control can be accomplished.
coaching intervention was a good method to reduce the treatment gap in applying evidence based medicine to the "real world" (25) . In the 4 years time between EUROASPIRE I and II no essential change in the risk factor's frequency were experienced while improvements were observed in the drug therapy (20, 21, 22, 26) . During this period of time the application of aspirin and beta-blockers increased 
